Olink to participate in the 43rd Annual Goldman Sachs Global Healthcare Conference
Olink Holding AB (Nasdaq: OLK) will participate in the 43rd Annual Goldman Sachs Global Healthcare Conference on June 14, 2022, at 2:00 pm PT / 5:00 pm ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Olink Holding AB (Nasdaq: OLK) will participate in the 43rd Annual Goldman Sachs Global Healthcare Conference on June 14, 2022, at 2:00 pm PT / 5:00 pm ET. Company management will take part in a fireside chat during the event. Interested parties can access a live and archived webcast of the discussion through the Investors section of Olink's website. Founded in 2016 and headquartered in Uppsala, Sweden, Olink is focused on accelerating proteomics to enhance patient outcomes through innovative scientific solutions.
Details
News Market Reaction – OLK
The recorded move for OLK in the trading session of this news was -2.64%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UPPSALA, Sweden, June 01, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced its participation in the 43rd Annual Goldman Sachs Global Healthcare Conference.
Company management will participate in a fireside chat on Tuesday, June 14th, 2022, at 2:00 pm PT / 5:00 pm ET.
A live and archived webcast of the event will be available on the “Investors” section of the Company’s website at https://investors.olink.com/investor-relations.
About Olink
Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The company was founded in 2016 and is well established across Europe, North America, and Asia. Olink is headquartered in Uppsala, Sweden.
Investor Contact
Jan Medina, CFA
VP Investor Relations & Capital Markets
Mobile: +1 617 802 4157
jan.medina@olink.com
Media Contact
Andrea Prander
Corporate Communications Manager
Mobile: +46 768 775 275
andrea.prander@olink.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.